Glenmark Pharmaceuticals Limited (NSE: GLENMARK)
India
· Delayed Price · Currency is INR | Market Cap | 480.48B |
| Revenue (ttm) | 128.61B |
| Net Income (ttm) | -13.11B |
| Shares Out | 282.19M |
| EPS (ttm) | -46.48 |
| PE Ratio | n/a |
| Forward PE | 31.91 |
| Dividend | 2.50 (0.15%) |
| Ex-Dividend Date | Sep 16, 2024 |
| Volume | 1,001,895 |
| Open | 1,709.70 |
| Previous Close | 1,709.45 |
| Day's Range | 1,695.00 - 1,725.00 |
| 52-Week Range | 722.10 - 1,750.50 |
| Beta | 0.91 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 31, 2024 |
About Glenmark Pharmaceuticals
Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and sells generics, specialty products, and OTC pharmaceutical products in India, North America, Latin America, Europe, and internationally. The company provides branded and generic formulations in the therapeutic areas of dermatology, respiratory, oncology, cardiology, diabetic, gynecology, gastroenterology, and anti-infective in the dosage forms of complex injectables and biologics, oral solids, liquids, topical products, drops, and respiratory/MDI/DPI/n... [Read more]
Financial Performance
Financial StatementsNews
Financial Crime Weekly: Drug Maker To Pay $25M For Price Fixing; Russians Busted For Propaganda; Nigerian Must Pay $5M For Phishing Scheme
Glenmark Pharmaceuticals Inc. USA , a generic pharmaceutical manufacturer in Mahwah, New Jersey, agreed to pay $25 million for allegedly conspiring to fix the price of a generic drug. The U.S. governm...
Glenmark Pharma settles US investigation with $25 million payment over five years
Glenmark Pharma Ltd. has reached a settlement with the US Department of Justice, agreeing to pay $25 million over five years to resolve an investigation into the company. This settlement is part of a ...
Glenmark Pharma shares hit record high after US Eye Allergy Drug launch
Glenmark Pharmaceuticals shares soared to a record high on Monday, following the launch of a new eye allergy drug in the US market by its subsidiary, Glenmark Therapeutics Inc.